Hyperlipidaemia and cardioprotection: Animal models for translational studies.
Ioanna AndreadouRainer SchulzLina BadimonAdriana AdameováPetra KleinbongardSandrine LecourPanagiota-Efstathia NikolaouInes Falcão-PiresGemma VilahurNicholas WoudbergGerd HeuschPéter FerdinandyPublished in: British journal of pharmacology (2020)
Hyperlipidaemia is a well-established risk factor for cardiovascular diseases and therefore, many animal model have been developed to mimic the human abnormal elevation of blood lipid levels. In parallel, extensive research for the alleviation of ischaemia/reperfusion injury has revealed that hyperlipidaemia is a major co-morbidity that attenuates the cardioprotective effect of conditioning strategies (preconditioning, postconditioning and remote conditioning) and that of pharmacological interventions by interfering with cardioprotective signalling pathways. In the present review article, we summarize the existing data on animal models of hypercholesterolaemia (total, low density and HDL abnormalities) and hypertriglyceridaemia used in ischaemia/reperfusion injury and protection from it. We also provide recommendations on preclinical animal models to be used for translations of the cardioprotective strategies into clinical practice. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc.
Keyphrases
- cerebral ischemia
- clinical practice
- risk factors
- subarachnoid hemorrhage
- cardiovascular disease
- acute myocardial infarction
- blood brain barrier
- brain injury
- endothelial cells
- ischemia reperfusion injury
- acute ischemic stroke
- physical activity
- electronic health record
- induced pluripotent stem cells
- single cell
- type diabetes
- left ventricular
- fatty acid
- heart failure
- case control
- benign prostatic hyperplasia
- percutaneous coronary intervention
- pluripotent stem cells
- lower urinary tract symptoms
- cell therapy
- acute coronary syndrome